PRU

Prudential Financial

$123.55

+0.93%
Nov 13, 2026
Bobby Quantitative Model
Prudential Financial, Inc. is one of the largest US life insurers, operating across annuities, life insurance, institutional retirement (notably pension risk transfer), group insurance, and asset management through its PGIM division, with the United States and Japan as its two principal markets and a growing presence in emerging markets such as Brazil. The company is a scale incumbent rather than a disruptor, distinguished by its roughly $1.47 trillion PGIM asset management platform and a diversified earnings base split approximately 50% US, 39% international, and 11% PGIM as of 2025 adjusted earnings. The current investor debate centers on a stark disconnect between reported headline results and underlying quality: the Q3 2026 print delivered an EPS beat ($4.03 diluted) but a significant revenue miss with revenue down 19.5% year over year, which has kept the sell-side firmly on the sidelines. Against that, the stock has been re-rated on a value and income thesis — a roughly 4.9% dividend yield, a discounted multiple, and relative strength versus a soft tape — leaving investors to weigh whether the earnings volatility is actuarial noise or a genuine deterioration in the franchise.

People also watch

MetLife

MetLife

MET

Analysis
Aflac

Aflac

AFL

Analysis
Unum

Unum

UNM

Analysis
Globe Life

Globe Life

GL

Analysis
Jackson Financial Inc.

Jackson Financial Inc.

JXN

Analysis

BobbyInvestment Opinion: Should I buy PRU Today?

Rating: Hold. The core thesis is that PRU is a genuinely cheap, cash-rich, high-yield life insurer whose 8.69x forward PE and 4.88% dividend yield already discount a great deal of bad news, but with zero Buy ratings among 15 analysts and a consensus target of $111.67 sitting roughly 6.4% below the current $119.24 price, the evidence does not yet support accumulation ahead of fundamental confirmation. The stock is a value-and-income holding, not a growth compounder, and the recent 13.35% one-year rally has moved it to roughly 74% of its 52-week range without a single sell-side upgrade to validate the move.

Supporting evidence is concentrated in valuation and cash generation rather than the top line. PRU trades at 11.05x trailing and 8.69x forward earnings with a PEG of 0.311, versus a life insurance sector that generally trades in the low-to-mid teens on forward PE, and at 1.22x book it sits in the lower-middle of its own multi-year range (down from 1.51x at year-end 2024). Free cash flow of $10.606 billion TTM against a ~$39.5 billion market cap implies a free cash flow yield near 27%, with $3.933 billion of operating cash flow generated in Q3 alone, funding both the $487 million dividend and $250 million of buybacks internally. The 4.88% yield is covered at a 53.86% payout ratio and supported by $18.739 billion of cash, while ROE of 11.02% and debt-to-equity of 0.708 show a solvent, shareholder-friendly balance sheet. The offset is that Q3 2026 revenue fell 19.5% year over year to $14.449 billion from $17.950 billion, and the sequential path ($15.546B, $15.661B, $14.449B) is deteriorating, so the cheap multiple is partly earned.

The biggest risks that could invalidate the value thesis are (1) Q3's 9.49% net margin proving to be actuarial noise rather than a new baseline, given the 5.87% trailing net margin and a swing from 3.84% in Q1 to 5.80% in Q2; (2) continued double-digit revenue erosion in the retirement/annuity book, which at $4.484 billion is the largest segment and the most rate- and market-sensitive; and (3) multiple compression if the sell-side's Underweight stance (Barclays, Wells Fargo, Morgan Stanley) persists and the $122–$127 supply zone caps rallies. This Hold would upgrade to Buy if net margin holds at or above 8% for two consecutive quarters and revenue stabilizes, or if the stock pulls back toward the $100–$105 zone where the forward PE would fall below 6x; it would downgrade to Sell on a break below the $113–$117 September shelf or a cut to the $17.50 consensus EPS. Net verdict: fairly valued to modestly undervalued on cash flow and book value, but not yet a compelling entry at $119.24 given consensus downside and unproven margin durability.

Sign up to view all

PRU 12-Month Price Forecast

PRU presents a classic value trap-versus-value opportunity debate: the 8.69x forward PE, 0.311 PEG, 1.22x book, and ~27% free cash flow yield are objectively cheap, and the 4.88% covered dividend offers a real return even if the multiple never re-rates. Against that, the sell-side is unanimous in its caution — zero Buys, 13 Holds, 5 Sells, and an average target of $111.67 that implies 6.4% downside — and the Q3 print showed an EPS beat masking a 19.5% revenue decline and a 9.49% net margin that is nearly double the 5.87% trailing level. The stock's 13.35% one-year gain and 18.82-point six-month relative strength versus SPY have been driven by the income and value thesis rather than by improving fundamentals, which is why the November 4 spike to $126.63 reversed to $119.24 within two sessions. I would upgrade to bullish if net margin holds at or above 8% for two consecutive quarters with revenue stabilizing, or if the stock pulls back toward $100–$105 where the forward PE drops below 6x; I would downgrade to bearish on a break below the $113–$117 shelf or a cut to the $17.50 consensus EPS.

Historical Price
Current Price $123.55
Average Target $111.50
High Target $136.00
Low Target $91.89

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Prudential Financial's 12-month outlook, with a consensus price target around $115.00 and implied upside of -6.9% versus the current price.

Average Target

$115.00

18 analysts

Implied Upside

-6.9%

vs. current price

Analyst Count

18

covering this stock

Price Range

$98 - $136

Analyst target range

Buy
0 (0%)
Hold
13 (72%)
Sell
5 (28%)

Coverage is broad but decidedly cautious: 15 analysts cover PRU with zero Buy ratings, 13 Holds, and 5 Sells, producing a consensus recommendation of "hold" and a recommendation mean of 3.44 (where higher scores indicate more bearish views). The average target price of $111.67 sits below the current price of $119.24, implying roughly 6.4% downside to consensus — an unusual configuration that signals the sell-side views the recent rally as having overshot fundamentals. The consensus leans bearish-to-neutral, and the absence of a single Buy among 15 analysts is a strong statement about conviction on the upside case.

The target range of $92.00 to $136.00 is wide — a 48% spread from low to high — indicating genuine disagreement about the earnings trajectory. The high target of $136.00 (about 14% above the current price) would require multiple expansion toward the mid-teens PE and validation that Q3's 9.49% net margin is sustainable rather than an actuarial one-off; the low target of $92.00 (roughly 23% below current) prices in margin compression, continued revenue erosion, and a return toward the 52-week low of $91.89. Institutional ratings show a consistent pattern of reaffirmations rather than upgrades — Barclays, Wells Fargo, and Morgan Stanley all maintain Underweight, while Piper Sandler, JP Morgan, TD Cowen, and KBW hold Neutral/Market Perform — with no upgrades in the recent tape, which combined with the wide target spread signals low conviction and elevated uncertainty around this name.

Drowning in data?

Find the real signal!

Bulls vs Bears: PRU Investment Factors

The bear case currently carries stronger evidence: zero Buy ratings, a consensus target 6.4% below the current price, a 19.5% revenue decline, and a post-earnings reversal off $126.63 all argue the recent 13.35% one-year rally has run ahead of fundamentals. The bull case rests on valuation and cash generation — 8.69x forward PE, a 0.31 PEG, a ~27% FCF yield, and a 4.88% covered dividend — which are genuinely compelling but have been compelling for several quarters without producing analyst upgrades. The single most important tension is whether Q3's 9.49% net margin is a durable new baseline or actuarial noise: if margins hold near that level, the forward PE of 8.69x is far too cheap and a re-rating toward the mid-teens is justified; if margins revert toward the 5.87% trailing level, the earnings base shrinks and the low target of $92 becomes the relevant anchor. Until revenue stabilizes and at least one analyst moves off Hold, the risk/reward favors patience over accumulation.

Bullish

  • Deep value multiple with PEG 0.31: PRU trades at 11.05x trailing and just 8.69x forward earnings, a ~21% compression that implies the market expects meaningful EPS growth. The PEG ratio of 0.311 is among the lowest in large-cap financials, pricing in stagnation even though consensus forward EPS of $17.50 points the other way.
  • Free cash flow yield near 27%: TTM free cash flow of $10.606 billion against a ~$39.5 billion market cap implies a free cash flow yield near 27%, with $3.933 billion of operating cash flow generated in Q3 alone. This internally funds the dividend and buybacks ($487 million and $250 million returned in Q3) without external financing dependence.
  • 4.88% dividend yield, 54% payout: The 4.88% yield is well covered by a 53.86% payout ratio and backed by $18.739 billion of cash at period end. For income-oriented investors this is a top-decile yield in the life insurance sector, and the low beta of 0.828 makes the income stream relatively stable.
  • Sequential margin recovery into Q3: Net margin expanded from 3.84% in Q1 to 5.80% in Q2 to 9.49% in Q3, while gross margin rose from 28.65% to 34.65% over the same span. Q3 EPS of $4.03 diluted beat expectations, suggesting the earnings beat was driven by margin recovery and favorable underwriting rather than volume.

Bearish

  • Zero Buy ratings among 15 analysts: Coverage is 0 Buy, 13 Hold, and 5 Sell, with a recommendation mean of 3.44 and an average target of $111.67 — roughly 6.4% below the current $119.24 price. The absence of a single Buy and a consensus target below market is a strong statement that the sell-side views the rally as having overshot fundamentals.
  • Revenue down 19.5% year over year: Q3 2026 revenue of $14.449 billion fell from $17.950 billion in Q3 2025, and the sequential path ($15.546B, $15.661B, $14.449B) is deteriorating. The decline is concentrated in the rate- and market-sensitive retirement/annuity engine, which at $4.484 billion is the largest segment.
  • Earnings quality is actuarial noise: The 9.49% Q3 net margin versus a 5.87% trailing figure implies large quarter-to-quarter swings, and trailing operating margin of 7.64% is thin. The Q3 EPS beat came alongside a significant revenue miss and weak operational metrics, raising the question of whether the beat is repeatable or a one-off reserve/underwriting benefit.
  • Post-earnings reversal signals distribution: The stock spiked to $126.63 on November 4, then fell to $122.46 and $119.24 on ~2.08 million shares — a 2.63% single-session drop. Sellers using strength to exit after the print, with the $122–$127 zone already proven as supply, is a caution flag for momentum.

PRU Technical Analysis

PRU is in a constructive but choppy uptrend, with the current price of $119.24 up 13.35% over the past year and 18.28% over six months, though it sits roughly 7.4% below its 52-week high of $128.78 and about 29.8% above the 52-week low of $91.89 — placing it at approximately 74% of its 52-week range. That positioning signals a stock with positive momentum that has ceded some ground from its highs rather than one pressing against resistance, consistent with a maturing advance rather than an overextended breakout. The 22.51% maximum drawdown over the period underscores that this is a stair-step trend punctuated by sharp air pockets, not a smooth compounding move.

Short-term momentum is re-accelerating even as the intermediate trend has cooled: the 1-month change of +6.12% contrasts with a 3-month change of -1.68%, a classic pullback-then-recovery pattern. The relative strength data reinforces the divergence — PRU has outperformed SPY by 11.11 percentage points over one month and 18.82 points over six months, yet it lags by 3.11 points year-to-date, meaning the recent burst is recovery from an earlier underperformance rather than broad-based leadership. The most recent session is a caution flag: the stock fell 2.63% from $122.46 to $119.24 on volume of roughly 2.08 million shares, a sharp reversal immediately following the post-earnings spike to $126.63 on November 4, suggesting sellers are using strength to exit.

Key technical levels are well defined: resistance sits at the 52-week high of $128.78, and a decisive break above it — particularly on volume — would confirm the multi-month uptrend and likely open a test of the $130s, while the $122–$127 zone has already proven to be a supply area. Support rests at the 52-week low of $91.89, with intermediate support implied by the September consolidation around $113–$117; a breakdown below that shelf would signal the November earnings pop was a bull trap and refocus attention on the low. With a beta of 0.828, PRU is roughly 17% less volatile than the market, which argues for larger position sizing tolerance but also means the stock will likely lag in a sharp risk-on rally — the 8.88 short ratio further implies a heavily shorted float that can amplify both squeezes and liquidation cascades.

Beta

0.83

0.83x market volatility

Max Drawdown

-22.5%

Largest decline past year

52-Week Range

$92-$129

Price range past year

Annual Return

+14.6%

Cumulative gain past year

PeriodPRU ReturnS&P 500
1m+8.9%-2.3%
3m-1.3%-2.8%
6m+21.2%+2.1%
1y+14.6%+12.3%
ytd+8.5%+10.6%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

PRU Fundamental Analysis

The revenue trajectory is the central problem: Q3 2026 revenue of $14.449 billion fell 19.5% year over year from $17.950 billion in Q3 2025, and the sequential path has been uneven — $15.546 billion in Q1, $15.661 billion in Q2, then $14.449 billion in Q3. Within the disclosed segments, Retirement is by far the largest contributor at $4.484 billion, followed by Group Insurance at $1.753 billion and Individual Life at $1.174 billion, meaning the institutional retirement and annuity engine — the most rate- and market-sensitive book — drives the bulk of results and explains the volatility. The growth trend implies a business whose top line is being pressured by spread compression and market-driven fee revenue rather than a structural loss of customers, but the magnitude of the decline keeps the investment case dependent on earnings quality rather than revenue expansion.

Profitability remains solid at the net line even as the top line contracts: Q3 2026 net income was $1.371 billion on a 9.49% net margin, with gross margin of 34.65% and operating margin of 14.89%, and EPS of $4.03 diluted. Margins have been volatile quarter to quarter — gross margin was 28.65% in Q1, 32.04% in Q2, and 34.65% in Q3, while net margin moved from 3.84% to 5.80% to 9.49% — a clear sequential expansion that suggests the Q3 earnings beat was driven by margin recovery and favorable actuarial/underwriting results rather than volume. The trailing net margin of 5.87% and operating margin of 7.64% are thin in absolute terms but not unusual for a life insurer, where investment spread and reserve assumptions dominate reported earnings; the key question is durability, since a single quarter of 9.49% net margin against a 5.87% trailing figure implies meaningful quarter-to-quarter noise.

Balance sheet and cash generation are the strongest part of the story: free cash flow TTM is $10.606 billion, quarterly operating cash flow was $3.933 billion in Q3, and cash stood at $18.739 billion at period end. Debt-to-equity is a manageable 0.708, ROE is 11.02%, and the dividend is well covered with a payout ratio of 53.86% against a 4.88% yield — the company returned $487 million in dividends and $250 million in buybacks in Q3 alone. The weak spot is liquidity optics: the current ratio of 0.609 looks alarming, but for an insurer this reflects reserve and separate-account accounting rather than distress, and the $10.6 billion FCF against a $39.5 billion market cap implies a free cash flow yield near 27%, underscoring that the company funds its obligations and shareholder returns internally without meaningful external financing dependence.

Quarterly Revenue

$14.4B

2026-09

Revenue YoY Growth

-19.5%

YoY Comparison

Gross Margin

34.6%

Latest Quarter

Free Cash Flow

$10.6B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Group Insurance
Individual Life
Retirement

Open an Account, get $2 TSLA now!

Valuation Analysis: Is PRU Overvalued?

Because net income is positive ($1.371 billion in Q3 2026), the PE ratio is the appropriate primary metric, and the picture is one of deep value: the trailing PE is 11.05x while the forward PE is just 8.69x, a roughly 21% compression that implies the market expects earnings to grow meaningfully into next year. That gap is corroborated by the consensus EPS estimate of $17.50 for the forward period against a trailing EPS base that has been depressed by actuarial noise, and by a PEG ratio of 0.311 — among the lowest in large-cap financials — which suggests the stock is priced as if growth will stall even though estimates point the other way.

On peer comparison, PRU trades at a price-to-book of 1.22x, a price-to-sales of 0.648x, and an EV/EBITDA of 8.93x, with a dividend yield of 4.88% — a profile that sits at the value end of the life insurance sector, where book-value multiples in the 1.0x–1.5x range are typical and where PRU's 1.22x is mid-range rather than distressed. The 8.69x forward PE against a sector that generally trades in the low-to-mid teens represents a meaningful discount, and the 0.648x P/S is low even for an insurer with heavy investment-income revenue. The discount appears justified in part by the 19.5% revenue decline and the persistent earnings volatility, but the 11.02% ROE and 4.88% yield argue that the market is over-penalizing a franchise that still generates $10.6 billion in free cash flow.

Historically, PRU's own valuation band has been wide: PE ranged from 6.44x in Q3 2025 to 18.03x in Q2 2025, with a Q4 2025 reading of 10.90x and a Q1 2026 reading of 14.20x, while price-to-book has drifted from 1.51x at year-end 2024 down to 1.06x–1.33x through 2026. At 11.05x trailing PE and 1.22x book, the stock sits in the lower-middle of its own multi-year range — not at the euphoric highs but well off the 2022-era book multiples above 2.0x. That positioning suggests the market is pricing in modest expectations rather than optimism, leaving room for re-rating if margin expansion proves durable, but also warning that the multiple has repeatedly failed to hold above 1.5x book in recent years.

PE

11.0x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 5x~18x

vs. Industry Avg

11.7x

Industry PE ~11.7x*

EV/EBITDA

8.9x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on earnings volatility and revenue concentration. Q3 2026 revenue fell 19.5% year over year to $14.449 billion, and the retirement segment at $4.484 billion is the largest contributor, meaning the most rate- and market-sensitive book drives the bulk of results. Net margin has swung from 3.84% (Q1) to 5.80% (Q2) to 9.49% (Q3) against a 5.87% trailing figure, so a single quarter of favorable actuarial or underwriting results can flatter the headline; if that reverses, EPS of $4.03 is not a reliable run-rate. The current ratio of 0.609 looks alarming but reflects reserve and separate-account accounting rather than distress, and debt-to-equity of 0.708 is manageable — the real financial risk is that the 8.69x forward PE depends on $17.50 of consensus EPS that assumes margin durability the trailing record does not support.

Market and competitive risks are dominated by valuation compression and sector rotation. At 1.22x book and 11.05x trailing PE, PRU is not expensive in absolute terms, but its own multiple has repeatedly failed to hold above 1.5x book since 2024, and the 8.69x forward PE versus a sector trading in the low-to-mid teens reflects a discount the market has been unwilling to close. With a beta of 0.828, PRU is roughly 17% less volatile than the market, which means it will likely lag a sharp risk-on rally and offer limited hedge value in a rotation toward growth. The recent news flow reinforces the overhang: the Q3 EPS beat was "overshadowed by a significant revenue miss and weak operational metrics," and the sell-side has responded with reaffirmations of Underweight rather than upgrades, keeping a ceiling on multiple expansion.

The worst-case scenario is a margin reversion combined with continued revenue erosion. If Q3's 9.49% net margin proves to be an actuarial one-off and net margin reverts toward the 5.87% trailing level while revenue keeps declining at a double-digit pace, the forward EPS estimate of $17.50 would be cut materially and the stock would likely retest the analyst low target of $92.00 — roughly 23% below the current $119.24. A fuller de-rating toward the 52-week low of $91.89 would imply a loss of about 23% from current levels, consistent with the 22.51% maximum drawdown already experienced over the past year. The short ratio of 8.88 amplifies this path: a heavily shorted float can turn an earnings miss into a liquidation cascade, and the $113–$117 September consolidation shelf is the first line that, if broken, would confirm the November pop was a bull trap.

FAQ

The most severe risk is earnings quality: Q3 2026 net margin of 9.49% is nearly double the 5.87% trailing figure, and the quarterly path (3.84% in Q1, 5.80% in Q2, 9.49% in Q3) shows large swings, so a reversion would undercut the $17.50 consensus EPS that the 8.69x forward PE depends on. Second is revenue erosion concentrated in the retirement/annuity book, which at $4.484 billion is the largest segment and the most rate- and market-sensitive; Q3 revenue fell 19.5% year over year to $14.449 billion and the sequential path is deteriorating. Third is valuation and sentiment risk: with 0 Buys, 13 Holds, 5 Sells, a recommendation mean of 3.44, and a consensus target 6.4% below the current price, there is no analyst support to cushion a de-rating, and the $122–$127 zone has already proven to be supply. Fourth is technical and positioning risk: a short ratio of 8.88 on a heavily shorted float can amplify a liquidation cascade, and a break below the $113–$117 shelf would put the $91.89 52-week low back in play, roughly 23% below current levels.

The 12-month forecast splits into three scenarios. The base case carries 55% probability with a $105–$118 target range, assuming margins normalize between the 5.87% trailing and 9.49% Q3 figures, revenue keeps eroding modestly, and the multiple stays near 8.69x forward, leaving the 4.88% dividend as most of the total return. The bear case carries 25% probability with a $91.89–$92.00 range, triggered if Q3's margin proves a one-off and revenue keeps contracting at a double-digit pace, cutting the $17.50 EPS estimate and retesting the 52-week low. The bull case carries 20% probability with a $128.78–$136.00 range, requiring margin to hold at or above 8%, revenue to stabilize, and at least one analyst upgrade off the current zero-Buy consensus. The base case is most likely because it is the only path consistent with 13 Holds and a $111.67 average target that sits just below the current price.

On most absolute measures PRU screens as undervalued. It trades at 11.05x trailing and 8.69x forward earnings against a life insurance sector that generally trades in the low-to-mid teens on forward PE, at 1.22x book versus its own 1.51x at year-end 2024 and 2.0x+ in 2022, and at 0.648x sales and 8.93x EV/EBITDA. The PEG of 0.311 is among the lowest in large-cap financials, implying the market is pricing in stagnation even though consensus forward EPS of $17.50 points the other way. The caveat is that the discount is partly earned: revenue fell 19.5% year over year in Q3 2026, and the trailing PE has ranged from 6.44x in Q3 2025 to 18.03x in Q2 2025, so the multiple is volatile rather than stable. The market appears to be paying a fair-to-modestly-discounted price that embeds skepticism about margin durability — not a deep-value bargain, but not a premium either.

From a pure risk/reward standpoint the setup is balanced rather than compelling at $119.24. The upside case is anchored by an 8.69x forward PE, a 0.311 PEG, 1.22x book, and a 4.88% dividend yield covered at a 53.86% payout ratio, with $10.606 billion of TTM free cash flow implying a yield near 27%. The downside case is that the consensus target of $111.67 sits 6.4% below the current price with zero Buy ratings among 15 analysts, and the bear-case anchor of $92.00 implies roughly 23% downside if Q3's 9.49% net margin proves to be actuarial noise rather than a new baseline. The stock is also 29.8% above its 52-week low of $91.89 and just reversed 2.63% off the post-earnings spike to $126.63, suggesting sellers are using strength to exit. It is a reasonable buy for income-focused investors with a multi-year horizon who want the 4.88% yield and are comfortable with earnings volatility, and a poor entry for anyone expecting near-term multiple expansion or momentum follow-through.

PRU is better suited to a long-term income and value holding period than to short-term trading. The 4.88% dividend yield covered at a 53.86% payout ratio and the $10.606 billion TTM free cash flow provide a return stream that does not depend on multiple expansion, which rewards patience over a 2–3 year horizon. Short-term traders face a difficult setup: beta of 0.828 means the stock lags sharp risk-on rallies, the 22.51% maximum drawdown shows repeated air pockets, and the 2.63% single-session reversal from $122.46 to $119.24 after the November 4 spike to $126.63 shows how quickly momentum fades. Earnings visibility is also low given the net margin swing from 3.84% to 9.49% across three quarters, which argues against holding through prints for tactical gains. A minimum holding period of 12–24 months is appropriate, with the position sized as an income sleeve rather than a core growth allocation.